Sprint Bioscience AB (OSTO:SPRINT) Interest Expense: kr-5.5 Mil (TTM As of Mar. 2026)


OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr3.70
GF Value kr2.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sprint Bioscience AB Interest Expense?

Sprint Bioscience AB OSTO:SPRINT -9.09% 32 Interest Expense is kr-5.5 Mil as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sprint Bioscience AB's interest expense for the three months ended in Mar. 2026 was kr -0.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-5.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sprint Bioscience AB's Operating Income for the three months ended in Mar. 2026 was kr -14.3 Mil. Sprint Bioscience AB's Interest Expense for the three months ended in Mar. 2026 was kr -0.1 Mil. Sprint Bioscience AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sprint Bioscience AB  (OSTO:SPRINT) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sprint Bioscience AB's Interest Expense for the three months ended in Mar. 2026 was kr-0.1 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr-14.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr0.0 Mil.

Sprint Bioscience AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Sprint Bioscience AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sprint Bioscience AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Interest Expense Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 0.00 0.00 -0.04 -0.42

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 -0.68 -0.10 -4.67 -0.07
OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-5.5 Mil mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Interest Expense of kr-5.5 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Interest Expense too high?
Sprint Bioscience AB's current Interest Expense is kr-5.5 Mil. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Interest Expense compare to VRTX and REGN?
Sprint Bioscience AB's Interest Expense of kr-5.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Interest Expense is kr-5.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr3.70 — trading 69.7% above its estimated fair value. The current Interest Expense is kr-5.5 Mil. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Interest Expense is kr-5.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr3.70 is trading 69.7% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Interest Expense: kr-5.5 Mil
  • GF Value™: kr2.18 vs. price of kr3.70 (69.7% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.70
Price
kr2.18
GF Value